---
title: Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis.
nct_id: NCT01233739
overall_status: UNKNOWN
phase: PHASE4
sponsor: Juan A. Arnaiz
study_type: INTERVENTIONAL
primary_condition: Rhizarthrosis
countries: Spain
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01233739.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01233739"
ct_last_update_post_date: 2013-02-22
last_seen_at: "2026-05-12T06:27:34.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis.

**Official Title:** Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Measurement With Sensory and Quantitive Functional Tests and Concordance Analysis With Subjective Scales of Pain.

**NCT ID:** [NCT01233739](https://clinicaltrials.gov/study/NCT01233739)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 108
- **Lead Sponsor:** Juan A. Arnaiz
- **Conditions:** Rhizarthrosis
- **Start Date:** 2011-03
- **Completion Date:** 2013-04
- **CT.gov Last Update:** 2013-02-22

## Brief Summary

Patients who present rhizarthrosis diagnostic will be randomized to be treated with chondroitin sulfate or placebo during 24 weeks to study the effect of the treatment with objective and subjective indicators of pain and sensibility.

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* both sex patients
* age between 45 to 75 years
* with mechanical pain at the trapezium-thumb metacarpal joint of more than 3 months duration
* grade II or III Eaton \& Glickel rhizarthrosis radiological diagnose
* pain at inclusion of \>= 40 mm at a visual analogue scale
* without rehabilitation treatment or infiltration in the last 6 months
* who accept to participate and sign informed consent

Exclusion Criteria:

* patients with rhizarthrosis resulted from rheumatic disease
* patients with joint surgery or traumatic background
* illiterate patients or unable to understand informed consent
* patients with previous neuropsychopathology enough severe to unable participation at the study
* patients with peripheral sensory impairment due to diabetes, peripheral neuropathy or central neurological sequelae of disease in the affected limb that can alter sensory perception
* patients with coagulopathy
* inflammation for other process at the joint at study
* in treatment with non-steroidal anti-inflammatory drug in the last 7 days and/or corticosteroid in the last 30 days
* allergy or hypersensibility at chondroitin sulfate or its excipients
* pregnant or breastfeeding woman
```

## Arms

- **Placebo** (PLACEBO_COMPARATOR)
- **Chondroitin sulfate** (EXPERIMENTAL) — Administration of 2 capsules of 400 mg of chondroitin sulfate orally.

## Interventions

- **Chondroitin sulfate** (DRUG) — Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
- **Placebo** (DRUG) — Administration of 2 capsules of placebo orally.

## Primary Outcomes

- **Evaluation with visual analogue pain scale as mean at the last weak** _(time frame: 36 weeks)_

## Secondary Outcomes

- **Sollerman test** _(time frame: 36 weeks)_
- **Hand pressure force** _(time frame: 36 weeks)_
- **Thumb-index finger pincer force** _(time frame: 36 weeks)_
- **Dash test** _(time frame: 36 weeks)_
- **SF-12 test** _(time frame: 36 weeks)_
- **Mechanical sensitivity measured with electronic Von Frey filament** _(time frame: 36 weeks)_
- **vibratory and thermic sensibility threshold assisted by computer** _(time frame: 36 weeks)_
- **Use of paracetamol or other analgesic drugs** _(time frame: 36 weeks)_
- **Evolution of trapezium-thumb metacarpal joint by ultrasound scan** _(time frame: 36 weeks)_
- **Hematologic evaluation** _(time frame: 24 weeks)_
- **Biochemical evaluation** _(time frame: 24 weeks)_

## Locations (1)

- Hospital Clínic i Provincial de Barcelona, Barcelona, Catalonia, Spain — _RECRUITING_

## Recent Field Changes (last 30 days)

- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.hospital clínic i provincial de barcelona|barcelona|catalonia|spain` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01233739.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01233739*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*